Thrombosis Australia

Thrombosis Australia is a central information and resource hub for the community proudly brought to you by the Perth Blood Institute



Our Thrombosis Australia Advisory Panel consists of seven eminent Australian healthcare professionals.

Thrombosis Australia Advisory Panel

If you are a healthcare professional you can access the Thrombosis Australia Professionals site here:

Thrombosis Australia Professionals


May 2022 Influence of sex on development of thrombosis in patients with COVID-19

This observational research aimed to determine if sex was a determining factor for risk of thrombosis among COVID-19 patients. The study group consisted of 1885 men and 1009 women COVDI-19 hospitalised patients from 16 centres across Japan, from April to September 2021.

Mild and moderate levels of COVID-19 were similar between the groups, however, men had more severe COVID-19 at admission, 9.1% compared to women (5.7%). Males also developed thrombosis and received pharmacological thromboprophylaxis more often than females. Understanding that men have more severe COVID-19 than women could be useful in forming a patient-specific optimal management strategy.

April 2022 Risk of venous thromboembolism after COVID-19 vaccination

This US study looked at the occurrence of VTE before and after vaccination over a 12-month period (November 2020-2021). There were 792,010 participants who had at least one vaccination: Pfizer (452,950), Moderna (290,607) and Johnson & Johnson (48,453) with the average age being 57 years.

Results found that 772 VTE events were recorded 90 days prior to vaccination and 793 (489 had DVT and 426 had PE) events 90 days after a vaccine being administered. The overall incidence rates were similar per 1000 person-years at 4.0 pre-vaccination and 4.1 post-vaccination.

April 2022 Risks of DVT, PE and bleeding after COVID-19

This study consisted of just over 1 million people who tested positive for SARSCoV-2 between 1 February 2020 and 25 May 2021 in Sweden and a control group of approx. 4 million participants. The results found that after having COVID-19 there was an increased risk for deep vein thrombosis after three months, for pulmonary embolism after six months, and bleeding at two months.

The study also found a higher risk for these conditions in patients with comorbidities or had more severe symptoms associated with COVID-19. Patients who had COVID-19 in the first wave also were at higher risk compared to those in the second wave.

These results provide useful information which could impact recommendations for diagnosis and preventative strategies against DVT, PE and bleeding after having COVID-19.

February 2022 Contribution of the elevated thrombosis risk of males to the excess male mortality observed in COVID-19

This observational study measured the rate of thrombotic diagnoses among COVID-19 patients during hospitalisation in both males and females and the mortality rate when evidence of thrombosis was present. The study found males had a 35.8% higher rate of receiving a thrombotic diagnosis compared with females. The mortality rate of all patients with a thrombotic diagnosis was 40.0%, more than twice that of patients with COVID-19 without a thrombotic diagnosis. COVID-19 male mortality rate was also higher at 29.9% which could be explained by an increased thrombotic risk.

February 2022 Adenovirus-Based Vaccines and Thrombosis in Pregnancy

There have been rare cases of thrombosis and thrombocytopenia (TTS) associated with the AstraZeneca and Johnson & Johnson COVID-19 vaccine, which are adenovirus-based vaccines. As most cases of TTS occurs in women of childbearing age, pregnancy as an important risk factor was investigated.

The review included studies from 1966 to 2021 and from 28 studies containing 1731 women. Analysis comprised of adenovirus-based vector vaccines to document cases of thrombocytopenia and coagulopathy. Over this period of time, no coagulopathy events were reported.

January 2022 COVID-19 vaccination and cerebral venous sinus thrombosis

Cerebral venous sinus thrombosis (CVST) has been reported following COVID-19 vaccination. This observational prospective study aimed to investigate any increased risk to patients with prior CVST after receiving a COVID-19 vaccination.

Of the 62 patients with prior CVST, 43 received Pfizer-BioNTech, 7 patients received Moderna mRNA-1273 and 7 received ChAdOx1 with 5 receiving Janssen Ad26.COV2.S. From these cases, no thrombotic events reoccurred within 30 days after vaccination. Despite the small sample size of this study, the data supports that COVID-19 vaccines are safe in patients who have previously had CVST.

December 2021 Research - COVID-19 and the risk of thrombosis

Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge.

The study found that extended post-discharge thromboprophylaxis with rivaroxaban for 35 days when compared with no anticoagulation, resulted in better clinical outcomes, including a reduction in major and fatal thromboembolic events without increasing major bleeding.

June 2021 - ATAGI & THANZ COVID-19 Vaccine Statement

March 2021 - Message from our CEO

March 2021 - Symptoms of VTE after COVID-19 vaccination

April 2020 - COVID-19 and Thrombosis - International Society of Thrombosis and Haemostasis

March 2020 - Impact on blood transfusions and blood donations

COVID-19 National Guidelines for Public Health Units

These guidelines provide nationally consistent guidance on how to respond to coronavirus (COVID-19).